What Is Retatrutide?
Retatrutide (CAS 2381089-83-2; also known as LY3437943) is a 39-amino acid synthetic peptide engineered as a triple agonist of three distinct metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG). Its structure carries a C-20 fatty diacid conjugated to the peptide backbone, extending the plasma half-life. CertaPeptides supplies retatrutide in lyophilized powder form from 2mg through 60mg per vial.
CAS: 2381089-83-2. Alternate identifier: LY3437943. Molecular weight: 4703.5 g/mol. Receptor-engagement profile: GIP-R, GLP-1R, and GCG-R simultaneously.
How Retatrutide Is Studied in the Literature
Retatrutide is characterised in the published peptide-research literature primarily through its triple-receptor pharmacology and its effects in preclinical metabolic models. The notes below describe the research context in which the molecule is investigated. They are reported for scientific background only and are not claims about what CertaPeptides’ research compound will do in any individual.
Body-composition and energy-expenditure research
In preclinical and in-vitro metabolic models, retatrutide is studied for its effects on body composition, adiposity, and energy-expenditure pathways. Researchers investigate how simultaneous engagement of GIP-R, GLP-1R, and GCG-R modulates these processes relative to single- and dual-receptor agonists.
Glucose-regulation pathway research
Retatrutide is also investigated in metabolic models for its role in glucose-regulation and incretin signalling pathways, including the dose-dependent receptor pharmacology that underlies its activity at the three target receptors.
Within the Incretin Class — How Retatrutide Differs
Retatrutide is studied alongside two other research peptides in the same metabolic class: semaglutide (single GLP-1R agonist) and tirzepatide (dual GIP/GLP-1R agonist). The three differ structurally and mechanistically in ways that shape how each compound is studied:
| Feature |
Semaglutide |
Tirzepatide |
Retatrutide |
| Receptor engagement |
GLP-1R (single) |
GIP-R + GLP-1R (dual) |
GIP-R + GLP-1R + GCG-R (triple) |
| Amino acid count |
31 |
39 |
39 |
| Molecular weight |
4113.58 Da |
4813.5 Da |
4703.5 Da |
| Unique mechanistic element |
Fatty-acid modification extends half-life at GLP-1R |
Imbalanced biased agonism favouring GIP-R |
Glucagon-receptor engagement adds hepatic glucose output & energy expenditure signals |
The glucagon-receptor arm is the distinguishing feature: neither semaglutide nor tirzepatide activates GCG-R. In research contexts this is of interest because glucagon agonism increases hepatic glucose output and thermogenesis, adding an energy-expenditure component not present in the single- or dual-agonist compounds. Researchers comparing the three frequently reference the GLP-1 class comparison overview and the molecular-level triple-receptor mechanism overview.
Research Areas Where Retatrutide Is Studied
- GIP, GLP-1, and glucagon receptor pharmacology — comparative in vitro binding and signalling assays
- Preclinical metabolic models of body composition and energy expenditure
- Comparative studies against single- and dual-agonist compounds (semaglutide, tirzepatide)
- Lipid metabolism and hepatic glucose-output pathways (glucagon-arm specific)
- Formulation and stability research for long-acting peptide analogues
Specifications
| CAS Number |
2381089-83-2 |
| Alternate identifier |
LY3437943 |
| Molecular Weight |
4703.5 g/mol |
| Receptor profile |
Triple agonist: GIP-R / GLP-1R / GCG-R |
| Purity |
≥ 98% (supplier batch spec; 99.4% avg across independently tested lots) |
| Physical Form |
Lyophilized (freeze-dried) powder in sealed glass vial |
| Available Sizes |
5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg |
Retatrutide is only a laboratory research compound. The above background information on the research comes from published scientific literature and is presented here in a brief manner. This is not a medical statement and does not indicate what effect the research materials will have on any individual. This product is not a drug, dietary supplement or cosmetic, nor has it been approved by the FDA, EMA or any other regulatory agency. It cannot be sold as an over-the-counter drug for human or veterinary use. This product is not used for diagnosis, treatment, cure, prevention or relief of any disease or symptom. It is for laboratory research purposes only. It is prohibited for human consumption.
评价
目前还没有评价